Astrazeneca Pharma India Ltd Q3FY25; 69% fall in Profits

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.

Financial Results:

Astrazeneca Pharma India Ltd reported Revenues for Q3FY25 of ₹1,050.00 Crores up from ₹955.00 Crore year on year, a rise of 9.95%.

Total Expenses for Q3FY25 of ₹957.00 Crores up from ₹887.00 Crores year on year, a rise of 7.89%.

Consolidated Net Profit of ₹64.00 Crores down 69.38% from ₹209.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹1.14, down 68.25% from ₹3.59 in the same quarter of the previous year.